Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.

Freedman, Arnold S.; Takvorian, Tak; Neuberg, Donna; Mauch, Peter; Rabinowe, SN; Anderson, KC; Soiffer, RJ; Spector, N; Grossbard, Michael L.; Robertson, M. J.

doi:10.1200/jco.1993.11.5.931

Cited by 99 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These transplant protocols have been published. [10][11][12][13][14] Quality of life instruments Patients were surveyed by mail before hospital admission and at 6 and 12 months post HCT. The survey solicited qualitative information on symptoms, self-assessment of health, feelings about the transplantation procedure and sense of recovery after transplantation.…”

Section: Patientsmentioning

confidence: 99%

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Andorsky

Loberiza

Lee

2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Previous studies of quality of life (QOL) note compromised QOL after stem cell transplantation (HCT), but do not usually consider the impact of pre-transplantation deficits in QOL on post transplantation outcomes. To examine these associations, multivariate models for six self-reported QOL outcomes at 6 and 12 months were constructed, considering pre-transplantation clinical status and QOL, and subsequent clinical events. Outcomes measured overall subjective health, social functioning and agreement with statements such as 'Life has returned to normal.' Of 320 autologous and allogeneic HCT recipients who completed pre-transplantation surveys, 197 completed 6-month surveys and 175 completed 12-month surveys. Pre-transplantation overall health and mental health were independent predictors of all QOL outcomes at 6 months. Baseline physical health was also predictive of four of six outcomes at 12 months. In contrast, disease risk was predictive only of enjoying normal activities at 6 months. Relapse and chronic graft-versus-host disease were associated with poorer QOL. In conclusion, pretransplantation self-reported physical and mental health are more strongly associated with QOL after HCT than commonly noted baseline clinical predictors such as age and disease risk. Measurement of baseline QOL can help place the effects of the transplantation procedure in context.

show abstract

Section: Patientsmentioning

confidence: 99%

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Andorsky

Loberiza

Lee

2006

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Results were highly promising, showing that such a strategy could improve CR and survival rates. [8][9][10][11][12] The Groupe d'Etude des Lymphomes de l'Adulte (GELA) reported the results of the LNH-87 protocol comparing sequential conventional-dose chemotherapy to high-dose therapy supported by ABMT. For patients with two or three factors of the Aa-IPI, relapse-free survival was significantly improved for transplanted patients.…”

Section: Introductionmentioning

confidence: 99%

Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high–intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin’s lymphoma: an oligocentric report on 42 patients

Bouabdallah

et al. 1999

Leukemia

View full text Add to dashboard Cite

We previously reported feasibility and efficacy of a monocentric pilot study of intensive sequential chemotherapy (ISC) in poor-risk aggressive non-Hodgkin's lymphoma (NHL) in patients Ͻ60 years. To validate these results on a large cohort of patients, we designed a new and oligocentric study. After a COP (cyclophosphamide (Cy), vincristine (Vcr), prednisone (Pred) debulking, patients received four courses of high-dose CHOP (Cy, doxorubicin (Doxo), Ver, Pred), with the addition of etoposide and cisplatin during the two last courses. G-CSF was delivered after each cycle, and peripheral blood stem cells (PBSC) were used to support the two last cycles. Total duration of chemotherapy was 13 weeks, with a planned dose-intensity (DI) of 1420 mg/m 2 /week and 23 mg/m 2 /week for Cy and Doxo, respectively. Radiotherapy (involved fields) was then delivered for patients with node size у5 cm at diagnosis. Forty-two patients were enrolled in this study; 36 completed the treatment and received 75% or more of the planned DI for both Cy and Doxo. Median duration of grade 4 neutropenia was 14 days (range, 2 to 28) for the regimen as a whole, and median duration of rehospitalization for febrile neutropenia was 18 days (range, 4 to 41). Overall response rate was 83%, with 29 patients (69%) in complete response (CR). Six patients failed to respond and one died of toxicity. With a median follow-up of 22.5 months (range, 10 to 42), the 3-year event-free survival (EFS) is 55% (95% CI, 39-71), while disease-free survival (DFS) is 79% (95% CI, 63-95). Ambulatory ISC is accessible and feasible in an oligocentric study. PBSC allow repeated delivery of high-dose chemotherapy cycles, and result in encouraging CR, EFS, and DFS rates for poor-risk aggressive NHL's patients.

show abstract

“…This approach has also been studied as a part of first-line therapy in NHL patients presenting with poor prognostic factors [13,14]. Furthermore, HDT is superior to conventional chemotherapy in terms of complete remission rate, event-free survival, and overall survival in MM patients [15].…”

Section: Discussionmentioning

confidence: 99%

Feasibility and toxicity of high‐dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non‐Hodgkin's lymphoma: Survey from a single institution

et al. 2003

View full text Add to dashboard Cite

The aim of this retrospective study was to investigate the feasibility of high-dose therapy (HDT) followed by peripheral blood stem cell transplantation (PBSCT) in elderly patients with hematological malignancies. From April 1998 to November 2001, 40 elderly patients (defined as ≥60 years) with non-Hodgkin's lymphoma (12 patients) and multiple myeloma (28 patients) were evaluated. Seven lymphoma and one myeloma patients were in complete remission (CR), 27 in partial remission (PR), two had stable disease (SD), and three progressive disease (PD). The median age was 65 years (range 60-71). Thirty-nine patients were mobilized with chemotherapy plus granulocyte-colony stimulating factor (G-CSF) and one with G-CSF alone. Patients received HDT including melphalan alone in 32 cases or combined with other drugs in six and BEAM in two. The median number of collected CD34 + cells was 12.4 × 10 6 /kg (range 2.0-68.9). The median number of re-infused CD34 + cells was 9.9 × 10 6 /kg (range 2.0-68.9). All patients engrafted after PBSC and the median time to neutrophil recovery (N > 500/µl) and platelet recovery (PLT > 20,000/µl) was 8 days (range 5-18) and 6 days (range 5-18), respectively. Nonhematological toxicity was mild and no patient died from transplant-related toxicity (TRM). Median duration of hospitalization was 18 days (range 12-24). To date, 32 patients are alive and eight died from disease progression at a median follow-up interval of 24 months. HDT supported by PBSC is a feasible procedure in selected elderly patients, and an age of more than 60 years should not be considered a contraindication for HDT. Am.

show abstract

Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.

Abstract: This pilot study suggests that consolidation of first remission with ABMT may improve the long-term DFS rate for diffuse intermediate/high-grade NHL patients at high risk for relapse.

Cited by 99 publications

References 0 publications

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high–intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin’s lymphoma: an oligocentric report on 42 patients

Feasibility and toxicity of high‐dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non‐Hodgkin's lymphoma: Survey from a single institution

Contact Info

Product

Resources

About